SecBot SecBot
SECBOTREPLAY Home › Report › XENE

XENE · Xenon Pharmaceuticals reported a Q4 2025 EPS miss of -9.4% versus…

Xenon Pharmaceuticals Inc. · PRESS-RELEASE filed Apr 15, 2026 at 08:30 ET

At the news

BEARISHIMPACT 5/10

PRESS-RELEASE filed Apr 15, 2026 at 08:30 ET

Xenon Pharmaceuticals reported a Q4 2025 EPS miss of -9.4% versus consensus, with actual EPS at $-1.31 compared to an estimated $-1.20. The press release contains no financial results or operational updates, only investor conference announcements.

  • Reported EPS of $-1.31 missed consensus estimate of $-1.20 by 9.4%, indicating worsening losses.
  • No revenue or operating metrics were disclosed in the release; only investor event schedule was provided.
  • Company announced upcoming presentations at four investor conferences in Q2 2026, but no new clinical or financial data.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access